{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260608910791/en/Septerna-to-Present-Preclinical-Characterization-of-SEP-479-an-Oral-PTH1R-Agonist-for-Hypoparathyroidism-at-2026-ENDO-Annual-Meeting", "message": "News view counter 785866 successfully enlarged"}